Viewing Study NCT06255418



Ignite Creation Date: 2024-05-06 @ 8:07 PM
Last Modification Date: 2024-10-26 @ 3:20 PM
Study NCT ID: NCT06255418
Status: COMPLETED
Last Update Posted: 2024-02-16
First Post: 2024-02-04

Brief Title: Big Data to Assess the Healthcare and Health Outcomes Burden of Acute Coronary Syndromes Complicated With Heart Failure
Sponsor: Hospital Universitari de Bellvitge
Organization: Hospital Universitari de Bellvitge

Study Overview

Official Title: Big Data and Real-world Evidence to Assess the Healthcare and Health Outcomes Burden of Acute Coronary Syndromes Complicated With Heart Failure the BEAT-HF Study
Status: COMPLETED
Status Verified Date: 2024-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: BEAT-HF
Brief Summary: The goal of this observational study is to define the incidence of heart failure HF after acute coronary syndrome ACS The main question it aims to answer is

To define HF incidence in the medium and long-term in the context of public healthcare coverage ensuring universal access to early coronary revascularization after ACS and extended neurohormonal treatment

Analyses will cover the entire population of Catalonia North-Eastern region of Spain N 7860563 in 2020

Researchers will compare HF incidence rate according to relevant subgroup characteristics including event type age groups or sex inter alia
Detailed Description: The aim of this project is to gain a better understanding from a population perspective of incident heart failure HF after acute coronary syndrome ACS The particular purpose is to define its incidence in the medium and long-term in the context of public healthcare coverage ensuring universal access to early coronary revascularization after ACS and extended neurohormonal treatment To provide answer to this objective a retrospective study were designed where a variety of study designs and analytic approaches will be used aimed at maximizing the robustness of the results and at minimizing their sensitivity to specific study design assumptions Analyses will cover the entire population of Catalonia Spain N 7860563 as of December 31st 2020 a region in which the Catalan Health Service granted universal health coverage The study period will be defined between January 1st 2012 and December 31st 2021 covering 10 years Inclusion criteria will be to have been admitted and diagnosed with a primary diagnosis of ACS non-ST-segment elevation myocardial infarction -NSTEMI- ST-segment elevation myocardial infarction -STEMI- unstable angina -UA- during the index event and to have been discharged alive during this period The first co-primary outcome is to define the baseline characteristics of the ACS population overall and according to clinical interest groups including event type STEMI NSTEMI UA and other relevant subgroups of patients The second co-primary outcome of the study is the incidence rate of HF after ACS of all patients discharged alive after an ACS in Catalonia during this period Incidence rate will also be described overall and according to relevant subgroup characteristics including event type clinical phenotypes surrogate of impairment in regional or global systolic function age groups sex diabetes mellitus HF complicating index ACS recurrent ACS after index ACS socioeconomic status treatments comorbidity groups and procedures Other clinical outcomes will be assessed as secondary outcomes all-cause death stroke recurrent ACS hospitalizations major adverse cardiac event etc

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None